Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma withFGFR3Alterations
| Autor: | Dale Porter, Sunil Sharma, Juergen Wolf, Jae-Lyun Lee, Kun Yu, Matthew D. Galsky, Jan H.M. Schellens, Daniel P. Petrylak, Ugo De Giorgi, Jean H. Hoffman-Censits, Jean Pierre Delord, Jonathan E. Rosenberg, Raanan Berger, Amir Mortazavi, Chaiyut Charoentum, Christian Dittrich, Ulka N. Vaishampayan, Randi Isaacs, Dean F. Bajorin, Katie Parker, Gwenaelle Gravis, Diana Graus Porta, Xueying Chen, Howard A. Burris, Jens Voortman, Eliahu Gez, David I. Quinn, Pablo Maroto, Bhumsuk Keam, David J. Vaughn, Viktor Grünwald, Sumanta K. Pal, Sumati Gupta, Virote Sriuranpong, J. Medioni |
|---|---|
| Přispěvatelé: | Medical oncology, CCA - Cancer Treatment and quality of life |
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine Urologic Neoplasms medicine.medical_specialty Metastatic Urothelial Carcinoma Constipation Administration Oral Antineoplastic Agents Disease Gastroenterology Article 03 medical and health sciences Hyperphosphatemia 0302 clinical medicine Internal medicine medicine Clinical endpoint Humans Receptor Fibroblast Growth Factor Type 3 Receptor Fibroblast Growth Factor Type 1 Aged business.industry Phenylurea Compounds Fibroblast growth factor receptor 1 Cancer Middle Aged medicine.disease Pyrimidines Treatment Outcome 030104 developmental biology Oncology 030220 oncology & carcinogenesis Mutation Toxicity Female medicine.symptom business |
| Zdroj: | Cancer Discovery r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Cancer discovery, 8(7), 812-821. American Association for Cancer Research Inc. Pal, S K, Rosenberg, J E, Hoffman-Censits, J H, Berger, R, Quinn, D I, Galsky, M D, Wolf, J, Dittrich, C, Keam, B, Delord, J-P, Schellens, J H M, Gravis, G, Medioni, J, Maroto, P, Sriuranpong, V, Charoentum, C, Burris, H A, Grünwald, V, Petrylak, D, Vaishampayan, U, Gez, E, de Giorgi, U, Lee, J-L, Voortman, J, Gupta, S, Sharma, S, Mortazavi, A, Vaughn, D J, Isaacs, R, Parker, K, Chen, X, Yu, K, Porter, D, Porta, D G & Bajorin, D F 2018, ' Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations ', Cancer discovery, vol. 8, no. 7, pp. 812-821 . https://doi.org/10.1158/2159-8290.CD-18-0229 |
| ISSN: | 2159-8290 2159-8274 |
| Popis: | BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of FGFR3 alterations. Patients (N = 67) who were unable to receive platinum chemotherapy were enrolled. The majority (70.1%) had received two or more prior antineoplastic therapies. BGJ398 was administered orally at 125 mg/day on a 3 weeks on, 1 week off schedule until unacceptable toxicity or progression. The primary endpoint was the response rate. Among 67 patients treated, an overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization, translating to a disease control rate of 64.2%. The most common treatment-emergent toxicities were hyperphosphatemia, elevated creatinine, fatigue, constipation, and decreased appetite. Further examination of BGJ398 in this disease setting is warranted.Significance: BJG398 is active in patients with alterations in FGFR3, resulting in both reductions in tumor volume and stabilization of disease. Our data highlight putative mechanisms of resistance to the agent, which may be useful in following disease status. Cancer Discov; 8(7); 812–21. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 781 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|